Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways

24 Jul 2020

Abstract excerpt

Rhabdomyosarcoma (RMS) is the most frequent form of pediatric soft-tissue sarcoma. It is divided into two main subtypes: ERMS (embryonal) and ARMS (alveolar). Current treatments are based on chemotherapy, surgery, and radiotherapy. The 5-year survival rate has plateaued at 70% since 2000, despite several clinical trials. RMS cells are thought to derive from the muscle lineage. During development, myogenesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to RNA modifications and cancer
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32728477
DOI: 10.1038/s41420-020-00302-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathwaysPMID 32728477Read ↗

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells via modulating metabolism and death pathwaysSemantic proximity Read ↗

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSemantic proximity Read ↗

Defining the gene expression signature of rhabdomyosarcoma by meta-analysisSemantic proximity Read ↗

Genetics, epigenetics and redox homeostasis in rhabdomyosarcoma: Emerging targets and therapeuticsSemantic proximity Read ↗

SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and Ongoing Clinical TrialsSemantic proximity Read ↗

High-level dynein impairs mitochondrial distribution and differentiation of rhabdomyosarcoma cellsSemantic proximity Read ↗

Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Semantic proximity Read ↗

Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcomaSemantic proximity Read ↗

Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcomaSemantic proximity Read ↗

Integrative Multi-Omics Profiling of Rhabdomyosarcoma Subtypes Reveals Distinct Molecular Pathways and Biomarker SignaturesSemantic proximity Read ↗

PROX1 transcription factor controls rhabdomyosarcoma growth, stemness, myogenic properties and therapeutic targetsSemantic proximity Read ↗

Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.